FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2507602904> ?p ?o ?g. }

• W2507602904 endingPage "2612" @default.
• W2507602904 startingPage "2612" @default.
• W2507602904 abstract "Abstract MRD assessment is used for risk stratification, prognosis, and treatment decisions (eg, hematopoietic stem cell transplant (HSCT) recommendation) in adult and childhood ALL. In Ph+ ALL, three distinct assay methods may be used to detect MRD: polymerase chain reaction (PCR) for clonal immunoglobulin (IG) and T-cell receptor (TR) gene rearrangements, quantitative RT-PCR (RQ-PCR) measurement of BCR-ABL1 transcripts, and flow cytometry (Flow). If results vary by assay method, different treatment decisions might be made. To assess this possibility, we examined the concordance of MRD levels and corresponding HSCT recommendations across the three methods for measuring MRD in patients (pts) enrolled to CA180372, a phase 2 study of dasatinib added to standard of care chemotherapy in pediatric pts with newly diagnosed Ph+ ALL. CA180372 (Children's Oncology Group (COG) AALL1122) was a collaboration between the COG, EsPhALL (European Intergroup Study on Post Induction Treatment of Ph+ ALL), and Bristol-Myers Squibb. Prior to study initiation, validation and proficiency testing were completed for standardization of methods used to detect MRD and for interpretation of IG/TR and BCR-ABL1 in accordance with guidelines developed by the EuroMRD consortium. All Flow analyses were performed at Johns Hopkins University. All pts received continuous treatment with dasatinib (60 mg/m2/d starting at day 15 of induction therapy) added to successive blocks of the EsPhALL multiagent chemotherapy regimen for a maximum of 2 y. MRD was analyzed 4 times during therapy (induction IA/baseline, end induction IA, start high risk block 1 (HR1), and end HR block 3 (HR3)). Pts were recommended for HSCT if: · Start of HR1 ≥0.05% by IG/TR PCR (or by Flow), less than 3-log reduction in MRD as measured by RQ-PCR for BCR-ABL1 OR · Start of HR1 0.005-0.05% by IG/TR PCR (or by Flow) or any positivity by BCR-ABL1 AND MRD remains positive at any detectable level (providing the assay limit is at least 0.1%) at the end of HR3 Clinical decisions were based on a single MRDmethodology, with the hierarchy of IG/TR > BCR-ABL1 > Flow. In this report we evaluated the concordance in HSCT recommendation among all three MRD methods. A total of 106 pts >1 y and <18 y were treated. HSCT eligibility could be determined for 89 (84%) pts by IG/TR, 41 (39%) by BCR-ABL1, and 104 (98%) by Flow. HSCT eligibility could not be determined for 17 (16%) by IG/TR due to technical challenges in assay development, 65 (61%) by BCR-ABL1 due to assay-specific requirements not being met, and 2 (2%) by Flow due to data missing from the database. These data were used to conduct inter-assay HSCT recommendation comparisons (Table). Rates of concordance in HSCT recommendations varied from 79.5-89.7% across methods. Among the discordant HSCT recommendations observed between each pair-wise comparison, 6/9 (IG/TR vs Flow), 2/4 (IG/TR vs BCR-ABL1), and 4/8 (BCR-ABL1 vs Flow) numerical MRD results were within 1-log, but fell on opposite sides of the assay cutoff point; assay-specific protocol criteria resulted in discordant HSCT recommendation in those cases. All pts enrolled to CA180372 were followed by at least one MRD method. HSCT recommendations could be made for most (98%) pts by Flow, while HSCT recommendation by IG/TR could be made for 84% of pts. Only 39% of pts could be recommended for HSCT based on BCR-ABL1 results. The main reason that BCR-ABL1 results were available for fewer pts was the requirement for at least 10,000 copies at baseline in order to assess if a 3-log reduction was achieved. Re-evaluation of assay-specific requirements is warranted. The overall concordance in HSCT recommendation was approx 80-90% across all three MRD methods. Overall, HSCT recommendation would have differed in 14 pts. Discordance between assays may be attributable (in part) to protocol-specific criteria, assay-specific threshold cut points, and/or differences in MRD results over different marrow pulls. Outcome data are not mature enough at this time to know whether pts recommended against HSCT by one method have increased risk for relapse when found to be eligible for HSCT by another method. Figure 1. HSCT Recommendation Concordance, by MRD Method Figure 1. HSCT Recommendation Concordance, by MRD Method Disclosures Borowitz: Becton Dickinson Biosciences, Medimmune: Research Funding. Geese:BMS: Employment. Healey:Bristol-Myers Squibb: Employment. Gastier-Foster:Bristol-Myers Squibb: Research Funding. Hunger:Bristol-Myers Squibb: Employment; Jazz Pharmaceuticals; Sigma Tau Pharmaceuticals; Erytech: Honoraria." @default.
• W2507602904 created "2016-09-16" @default.
• W2507602904 creator A5006908499 @default.
• W2507602904 creator A5022541563 @default.
• W2507602904 creator A5023214494 @default.
• W2507602904 creator A5028215748 @default.
• W2507602904 creator A5051520180 @default.
• W2507602904 creator A5059812645 @default.
• W2507602904 creator A5066343875 @default.
• W2507602904 creator A5076365826 @default.
• W2507602904 creator A5076652172 @default.
• W2507602904 date "2015-12-03" @default.
• W2507602904 modified "2023-10-16" @default.
• W2507602904 title "International Laboratory Comparison of Methodologies for Determining Minimal Residual Disease (MRD) in Childhood Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)" @default.
• W2507602904 doi "https://doi.org/10.1182/blood.v126.23.2612.2612" @default.
• W2507602904 hasPublicationYear "2015" @default.
• W2507602904 type Work @default.
• W2507602904 sameAs 2507602904 @default.
• W2507602904 citedByCount "2" @default.
• W2507602904 countsByYear W25076029042020 @default.
• W2507602904 countsByYear W25076029042022 @default.
• W2507602904 crossrefType "journal-article" @default.
• W2507602904 hasAuthorship W2507602904A5006908499 @default.
• W2507602904 hasAuthorship W2507602904A5022541563 @default.
• W2507602904 hasAuthorship W2507602904A5023214494 @default.
• W2507602904 hasAuthorship W2507602904A5028215748 @default.
• W2507602904 hasAuthorship W2507602904A5051520180 @default.
• W2507602904 hasAuthorship W2507602904A5059812645 @default.
• W2507602904 hasAuthorship W2507602904A5066343875 @default.
• W2507602904 hasAuthorship W2507602904A5076365826 @default.
• W2507602904 hasAuthorship W2507602904A5076652172 @default.
• W2507602904 hasConcept C126322002 @default.
• W2507602904 hasConcept C143998085 @default.
• W2507602904 hasConcept C160798450 @default.
• W2507602904 hasConcept C203014093 @default.
• W2507602904 hasConcept C2776611710 @default.
• W2507602904 hasConcept C2776694085 @default.
• W2507602904 hasConcept C2777583451 @default.
• W2507602904 hasConcept C2778020697 @default.
• W2507602904 hasConcept C2778336483 @default.
• W2507602904 hasConcept C2778461978 @default.
• W2507602904 hasConcept C2778729363 @default.
• W2507602904 hasConcept C2779536868 @default.
• W2507602904 hasConcept C2779823535 @default.
• W2507602904 hasConcept C2909962599 @default.
• W2507602904 hasConcept C71924100 @default.
• W2507602904 hasConceptScore W2507602904C126322002 @default.
• W2507602904 hasConceptScore W2507602904C143998085 @default.
• W2507602904 hasConceptScore W2507602904C160798450 @default.
• W2507602904 hasConceptScore W2507602904C203014093 @default.
• W2507602904 hasConceptScore W2507602904C2776611710 @default.
• W2507602904 hasConceptScore W2507602904C2776694085 @default.
• W2507602904 hasConceptScore W2507602904C2777583451 @default.
• W2507602904 hasConceptScore W2507602904C2778020697 @default.
• W2507602904 hasConceptScore W2507602904C2778336483 @default.
• W2507602904 hasConceptScore W2507602904C2778461978 @default.
• W2507602904 hasConceptScore W2507602904C2778729363 @default.
• W2507602904 hasConceptScore W2507602904C2779536868 @default.
• W2507602904 hasConceptScore W2507602904C2779823535 @default.
• W2507602904 hasConceptScore W2507602904C2909962599 @default.
• W2507602904 hasConceptScore W2507602904C71924100 @default.
• W2507602904 hasIssue "23" @default.
• W2507602904 hasLocation W25076029041 @default.
• W2507602904 hasOpenAccess W2507602904 @default.
• W2507602904 hasPrimaryLocation W25076029041 @default.
• W2507602904 hasRelatedWork W2507602904 @default.
• W2507602904 hasRelatedWork W2952112720 @default.
• W2507602904 hasRelatedWork W3030916261 @default.
• W2507602904 hasRelatedWork W3093388244 @default.
• W2507602904 hasRelatedWork W3095280747 @default.
• W2507602904 hasRelatedWork W3161562332 @default.
• W2507602904 hasRelatedWork W4281551859 @default.
• W2507602904 hasRelatedWork W4308057391 @default.
• W2507602904 hasRelatedWork W4311165255 @default.
• W2507602904 hasRelatedWork W4382934820 @default.
• W2507602904 hasVolume "126" @default.
• W2507602904 isParatext "false" @default.
• W2507602904 isRetracted "false" @default.
• W2507602904 magId "2507602904" @default.
• W2507602904 workType "article" @default.